SITC is pleased to share that the updated acute leukemia CPG was accepted for publication in JITC and will soon be available.
This guideline in the culmination of work by the SITC acute leukemia expert panel in developing actionable evidence- and consensus-based recommendations to help clinicians select immunotherapeutic regimens for patients with ALL and AML.
The SITC Cancer Immunotherapy Guidelines program is a collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations on when and how to use immunotherapy to help improve outcomes for patients with cancer.
These CPGs offer a vital resource for the practicing oncology community. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure a fair, transparent and balanced process for creating the CPGs. Each CPG expert panel is comprised of a comprehensive mix of academic physicians and researchers, nurses, patients, and patient advocates invited from institutions across the United States.
Acute Leukemia Guideline
Breast Cancer Guideline
Gynecologic Cancer Guideline
Gastrointestinal Cancer Guideline
Head and Neck Squamous Cell Carcinoma Guideline
Hepatocellular Carcinoma Guideline
ICI-related Adverse Events Guideline
IEC-related Adverse Events Guideline
Lung Cancer and Mesothelioma Guideline
Lymphoma Guideline
Melanoma Guideline
Multiple Myeloma Guideline
Nonmelanoma Skin Cancer Guideline
Prostate Carcinoma Guideline
Renal Cell Carcinoma Guideline
Urothelial Cancer Guideline